# Sources — Sugar Ray Robinson

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

Accessed November 5, 2026. The canonical source metadata and claim links are in `case.json`.

## Historical evidence

1. United Press International. “Sugar Ray Robinson dead at 67,” April 12, 1989. Supports that he “died at a hospital Wednesday after suffering from Alzheimer's disease and diabetes. He was 67”; that he was taken by paramedics “to the emergency room at Brotman Medical Center in Culver City” and arrived in “full arrest”; that his wife said he “suffered from Alzheimer's and diabetes for years” and that his blood sugar “went sky high” that morning; that “over his career, Robinson had 201 fights,” winning “109 by knockout and 65 by decision”; that he “held the welterweight championship of the world once and the middleweight title five times”; that he was “born Walker Smith Jr.”; and that he was “born May 3, 1921, in Detroit” and moved “with his family to New York's Harlem as a boy.” https://www.upi.com/Archives/1989/04/12/Sugar-Ray-Robinson-dead-at-67/7942608356800/
2. United Press International. “Former boxing great Sugar Ray Robinson is suffering from Alzheimer's disease,” July 9, 1987, summarizing a Sports Illustrated article. Supports that at 65 he reportedly had Alzheimer's disease, diabetes and hypertension, depended on his wife for daily care and was “virtually incapable of speech”; the 1939 Golden Gloves featherweight title; the welterweight title in 1946 and the middleweight title in 1951; a record of 174-19-6 from 1940 to 1965; and the Sugar Ray Robinson Youth Foundation for inner-city children of Los Angeles. The report also describes a dispute among family members; that is not used. https://www.upi.com/Archives/1987/07/09/Former-boxing-great-Sugar-Ray-Robinson-is-suffering-from/5962552801600/
3. Michigan Sports Hall of Fame. “Sugar Ray Robinson,” inductee biography. Supports his birth name Walker Smith Jr., his birth in Ailey, Georgia, with the family later moving to Detroit, the 1939 Golden Gloves featherweight title, a record of “173 – 19 – 6 with 105 wins by knockout,” and his death on April 12, 1989, at 67. https://michigansportshof.org/inductee/sugar-ray-robinson/
4. Evans L, compiler. “Sugar Ray Robinson,” West Adams Heritage Association. Supports that in Los Angeles he and his wife “lived modestly in the top story of a duplex at the corner of West Adams Blvd”; that “in 1969 he founded the Sugar Ray Robinson Youth Foundation for inner-city children in the Los Angeles area”; and that, “suffering from Alzheimer's disease and diabetes,” he died at 67 on April 12, 1989, “at the Brotman Medical Center in Culver City.” https://westadamsheritage.org/read/457
5. Boxing News. “On this day: Sugar Ray Robinson, the most complete fighter to set foot in a ring, dies.” Used only for the end of his career. https://boxingnewsonline.net/features/on-this-day-sugar-ray-robinson-the-most-complete-fighter-to-set-foot-in-a-ring-dies
6. HISTMED Master Roster v3. Internal project source; not treated as independent corroboration.

## Clinical guidance

1. Dickerson BC, Atri A, et al. Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): executive summary of recommendations for specialty care. *Alzheimers Dement* 2025;21(1):e14337 (PMID 39713957); and the executive summary for primary care (PMID 39713942). A structured evaluation of cognition, function and behavior with an informant, first-tier laboratory tests, structural imaging, biomarker testing when it will inform the diagnosis, and disclosure and counseling for the patient and care partner. https://pubmed.ncbi.nlm.nih.gov/39713957/; https://pubmed.ncbi.nlm.nih.gov/39713942/
2. CMID: Clinical Monitoring Intelligence Database (Aether Forge, 2026), Alzheimer's disease monograph (with the dementia bundle: Beers medication review and neuropsychiatric screen every visit; driving, home safety and falls; cognitive testing, staging, ADL and IADL, depression screen, caregiver assessment and advance care planning at diagnosis and yearly; anti-amyloid eligibility, APOE and ARIA MRI schedules; cholinesterase inhibitor tolerability at each follow-up; GUIDE model), and the diabetes type 2 and hypertension monographs. https://patrickrutledge.github.io/topthirty/
3. Cummings J, et al. Lecanemab: Appropriate Use Recommendations. *J Prev Alzheimers Dis* 2023;10(3):362-377 (PMID 37357276): patients requiring anticoagulants should not receive lecanemab, APOE genotyping informs ARIA risk discussions, and clinician and institutional preparedness are mandatory. https://pubmed.ncbi.nlm.nih.gov/37357276/
4. Rabinovici GD, et al. Donanemab: Appropriate use recommendations. *J Prev Alzheimers Dis* 2025;12(5):100150 (PMID 40155270): candidates have MCI or mild dementia due to Alzheimer's disease (MMSE 20 to 30) with amyloid confirmed by PET or CSF; APOE genotyping before treatment; patients with more than four cerebral microbleeds, cortical superficial siderosis or a major vascular contribution should be excluded; MRI before the 2nd, 3rd, 4th and 7th infusions. https://pubmed.ncbi.nlm.nih.gov/40155270/
5. Katz DI, et al. National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome. *Neurology* 2021;96(18):848-863 (PMID 33722990): research criteria for the clinical syndrome associated with repetitive head impacts. https://pubmed.ncbi.nlm.nih.gov/33722990/
6. American Diabetes Association. 13. Older Adults: Standards of Care in Diabetes-2026. *Diabetes Care* 2026;49(Suppl 1):S277-S296 (PMID 41358888): individualized goals (A1c under 8.0% for older adults with mild to moderate cognitive impairment or multiple chronic illnesses), avoidance of hypoglycemia and deintensification of agents such as sulfonylureas. https://pubmed.ncbi.nlm.nih.gov/41358888/
7. American Geriatrics Society 2023 Beers Criteria (PMID 37139824): avoid first-generation antihistamines such as diphenhydramine in older adults, and sulfonylureas with a high hypoglycemia risk. https://pubmed.ncbi.nlm.nih.gov/37139824/
8. Iverson DJ, et al. Practice Parameter update: Evaluation and management of driving risk in dementia. *Neurology* 2010;74(16):1316-1324 (PMID 20385882): a CDR of 1 or more and a care partner's concern mark high driving risk. https://pubmed.ncbi.nlm.nih.gov/20385882/
9. Centers for Medicare & Medicaid Services Innovation Center. Guiding an Improved Dementia Experience (GUIDE) Model, for Medicare beneficiaries with dementia and their unpaid caregivers. https://www.cms.gov/priorities/innovation/innovation-models/guide
10. U.S. Preventive Services Task Force: colorectal cancer (2021), prostate cancer (2018), lung cancer (2021), abdominal aortic aneurysm (2019), statins (2022), HIV (2019), hepatitis C (2020), depression and suicide risk (2023), unhealthy alcohol use (2018), and the A and B recommendations. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations
11. Centers for Disease Control and Prevention. Adult Immunization Schedule by Age, and Screening and Testing for Hepatitis B Virus Infection, 2023 (PMID 36893044). https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html; https://pubmed.ncbi.nlm.nih.gov/36893044/
12. Medicare Preventive Services reference (Aether Forge, 2026). https://patrickrutledge.github.io/preventative_services/

## Editorial resolutions

- **Sources.** The case relies on two United Press International reports (the 1989 obituary and a 1987 report summarizing a Sports Illustrated article), the Michigan Sports Hall of Fame, the West Adams Heritage Association and Boxing News. The International Boxing Hall of Fame site refused the connection; the New York Times and Los Angeles Times obituaries could not be fetched; Britannica and BlackPast returned access errors; Wil Haygood's *Sweet Thunder* was not read, and the reviews found do not describe his illness. Nothing in the record rests on these.
- **Recent-death rule.** He died in 1989, so the rule does not apply and a sick visit is included. Because dementia claims are sensitive, only documented press reports are used: the 1987 report of Alzheimer's disease, diabetes and hypertension at 65, and the 1989 reports of Alzheimer's disease and diabetes at his death. These claims are marked sensitive. Hypertension rests on the single 1987 report (CLM-0009, certainty possible). No source dates his Alzheimer's diagnosis, so the modern episode makes no claim about when he was really diagnosed.
- **Dementia pugilistica.** The roster's “dementia pugilistica” and “probable boxing-related dementia” (and its G31.09 cluster code) are recorded only as an R claim (CLM-0010, possible): no source read records that diagnosis, chronic traumatic encephalopathy or an autopsy finding. In the modern episode, traumatic encephalopathy syndrome is weighed as a research diagnosis and is not put on the problem list.
- **Birth and birthplace.** The date, May 3, 1921, is consistent across the sources read. The birthplace is disputed: Ailey, Georgia (Michigan Sports Hall of Fame) or Detroit (1989 UPI obituary). Both are recorded in CLM-0001 and neither is used in the modern episode. The synthetic date of birth keeps the true month and day: 1963-05-03, a shift of 42 years.
- **Index age and dates.** He is 63 at the index visit on July 7, 2026, which maps to July 7, 1984, three years before the July 1987 report of advanced disease at 65, so that the episode falls at the stage of mild dementia. The visits on July 21, August 18, September 8, September 22, October 1 and October 27, 2026 (and the amyloid PET on August 4 and the hearing aid fitting on September 1) map to the same days of 1984, within his lifetime. He lived in Los Angeles from before 1969 (the foundation) to his death; his day-to-day whereabouts in 1984 are not documented in the sources read. Past medical history includes only events before the index date; the 1987 and 1989 health claims are linked only to later timeline events and are omitted from intake documents.
- **Name and alias.** The display name is Sugar Ray Robinson; the given name “Sugar Ray” and family name “Robinson” split normally, so identity.name_parts is not used. The alias is his birth name, Walker Smith Jr., which appears in no other record. “Walker” alone and “Robinson” alone are not aliases, since other records carry those words in their own names.
- **Career and exposure.** About 200 professional bouts from 1940 to 1965 (201 fights in the 1989 obituary; records of 174-19-6 and 173-19-6 in other sources), after an amateur career, is recorded as long exposure to repetitive head impacts (PMH-001, D). No source read gives a count of knockdowns or losses of consciousness, and the record does not invent one.
- **The care partner.** He lived with his wife in Los Angeles (documented). In the modern episode, the person who comes to visits, reports his symptoms, drives him, holds the key to the handgun and becomes his health care agent is a synthetic care partner who is unnamed and not modeled on any relative; no statement, decision or health fact in the modern episode is attributed to his wife or any other real relative. His wife appears only in documented claims (her statements to reporters in 1989, and the 1987 report that he depended on her). The 1987 report's account of a dispute among family members is not used. The youth foundation is documented history; in the modern episode he visits its gym, a synthetic detail.
- **Diagnoses and presenting problem.** Memory loss with getting lost (R41.3) is the presenting problem, resolved at the six-week visit when the amyloid PET confirmed Alzheimer's disease with early onset (G30.0) with mild dementia (F02.A0); onset before 65 makes the early-onset code correct. G30.0 and E11.9 are placed both_with_link because they are synthetic modern diagnoses anchored to documented illness. Bilateral sensorineural hearing loss (H90.3) was found at the consultation. The donepezil side effects at the sick visit are coded R11.0 (nausea). No safety assessment is required: F02 is excluded from the rule and the PHQ-9 was 4 and then 3.
- **Biomarkers and anti-amyloid therapy (judgment calls).** (1) Six microbleeds on MRI exclude him from lecanemab and donanemab under both appropriate use recommendations (more than four), so he is not a candidate whatever his amyloid status. (2) Amyloid PET was still done, because it settles the diagnosis he wanted to know, informs counseling and planning, and separates Alzheimer's disease from a mainly traumatic process; the 2025 donanemab recommendations require PET or CSF for treatment, so a blood test would not have been enough had he been a candidate. A plasma p-tau217 test was considered and not used. (3) APOE genotyping was not done: it would not change his care, it has implications for relatives, and he declined it after counseling. (4) The microbleed pattern and the cavum septi pellucidi are described as consistent with past head injury; this is a synthetic imaging finding, not a historical claim.
- **Instruments.** MoCA (72172-0), MMSE (72107-6), global CDR (72088-8), PHQ-2 and PHQ-9 are coded. The CDR sum of boxes, the Functional Activities Questionnaire, the Zarit Burden Interview, STOP-Bang, the Timed Up and Go and the neuropsychiatric symptom review are narrative. The MoCA includes the education point; scores are interpreted with his schooling in mind.
- **Medicines (judgment calls).** Diphenhydramine stopped at intake (Beers). Glipizide stopped at the diagnosis visit after a reading of 68 mg/dL with hemoglobin A1c 6.4%, under the ADA goal of under 8.0% for an older adult with cognitive impairment; metformin continued with sick-day rules. Donepezil 5 mg after a normal ECG, raised to 10 mg at five weeks, and returned to 5 mg each morning after nausea, loose stools, vivid dreams and a pulse of 56; he chose to stay at 5 mg rather than retry 10 mg or switch to a rivastigmine patch. Memantine is not used at the mild stage.
- **Safety.** He agreed to stop driving at the diagnosis visit (CDR 1 and getting lost while driving), after not driving during the work-up; the handgun, unloaded and locked from intake, was removed from the home. Both details (the car and the handgun) are synthetic.
- **GUIDE.** At 63 he is not on Medicare in the modern frame, so the GUIDE dementia care model is explained for when he enrolls (at 65, or earlier through disability); meanwhile the care partner uses the Alzheimer's Association helpline, a caregiver class and an adult day program for respite.
- **Care setting.** The project facility name (St. Posthumous Health Center) is kept; in the notes it has a memory clinic, an audiologist and an adult day program link. These are fictional features of a fictional clinic.
- **Relatives and others.** No relative is named in the modern episode, and none is given a statement, decision or health fact there. Other boxers and public figures are not named; other figures who have records in the dataset are not named.
- **Synthetic clinical picture.** Everything in the modern episode is synthetic: the symptoms, every score, all laboratory values, the MRI, audiometry, amyloid PET and ECGs, the medicines and their changes, the low glucose reading, the missed eye examination and the outcomes. Height (180 cm) and weights are synthetic.
- **Preventive visit.** A periodic adult preventive visit at 63 (CPT 99396 and 99497 in plain text). Judgment calls: HIV, hepatitis C and hepatitis B screening; colonoscopy up to date (a synthetic record of a normal colonoscopy six years earlier); PSA declined after shared decision-making with his dementia in view; lung and aneurysm screening not indicated; LDL 79 mg/dL on atorvastatin 20 mg, continued; diabetic foot examination normal; influenza, PCV20 and the first recombinant zoster dose, with Tdap at the next visit at his choice; RSV vaccine not indicated at 63 (no listed condition: diabetes without complications, no insulin or SGLT2 inhibitor); COVID-19 vaccine declined for now. Advance care planning was done early, while he could take part fully, with a capacity assessment; he named his care partner (unnamed here) as his agent and said he would want comfort-focused care at home and no feeding tube if he no longer knew the people close to him.
- **Sick visit.** Nausea, loose stools, vivid dreams, dizziness on standing and a slow pulse nine days after donepezil was raised to 10 mg, with mild dehydration (creatinine 1.2 mg/dL). Chosen because it follows from the plan, interacts with his diabetes and blood pressure medicines (sick-day rules: metformin and lisinopril held for 48 hours) and insinuates no undocumented diagnosis. An ECG showed sinus bradycardia without heart block. It is not a historical claim.
- **Focused visits.** The four chronic-care follow-ups (two weeks with the consultation, six weeks with the diagnosis, eleven weeks and sixteen weeks) are documented as focused visits on the CMID Alzheimer's disease (dementia bundle), diabetes and hypertension monographs, the DETeCD-ADRD guideline, the lecanemab and donanemab appropriate use recommendations, the ADA Standards for older adults, the Beers Criteria and the AAN driving parameter. One deviation is recorded instead of an invented result: the dilated diabetic eye examination requested at intake was missed because he no longer drove and the appointment was forgotten; no harm is known (no visual symptoms, good control), and the corrective action was paratransit, a same-morning reminder call to the care partner and the day program calendar; the examination was done before the sixteen-week visit (no retinopathy, narrative). Anti-amyloid monitoring is recorded as not indicated, with the reason. Synthetic findings introduced: the MRI and PET findings, the hearing loss, the low glucose reading, the missed eye examination, the donepezil side effects and the Zarit scores (18, then 16).
- **Consultation.** The cognitive neurology referral and consultation by Mireille Haddad-Kowalski, MD (a fictional consultant), on the day of the two-week visit, are **S**. The consultant answers the five referral questions in line with what the record shows afterwards: mild dementia (CDR 1) most consistent with Alzheimer's disease; traumatic encephalopathy syndrome a research consideration that does not change treatment, and vascular change slight; amyloid PET (positive two weeks later) and no APOE testing; not a candidate for lecanemab or donanemab because of six microbleeds; donepezil after a baseline ECG (started at six weeks, raised, then reduced for side effects), glipizide stopped (at six weeks), no driving, the firearm removed, hearing aids (fitted), care partner respite and GUIDE once on Medicare, and early advance care planning (done at the preventive visit). The consultant's history attributes nothing to any real relative; the care partner is synthetic.
